AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01342094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-111 ophthalmic solution
Study NCT01342094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol ophthalmic solution 0.5%
Study NCT01342094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ophthalmic solution
Study NCT01342094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo ophthalmic solution
Study NCT02004626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Collagenase
Description: Conduction of security tests: complete coagulation and glycosylated hemoglobin. Volunteers in childbearing age, with β-HCG (human chorionic gonadotropin) test.~Verification of anthropometric data, clinical evaluation, PU evaluation, randomization and treatment start.~Wash the wound with 0.9 % sterile saline solution; Apply of the investigational product directly in the devitalized tissue (necrotic tissue and Slough).~Cover the wound with sterile gauze and dry transparent film. The procedures for the exchange of bandages must be done every day, twice a day until the total debridement of devitalized tissue.~Photographic records.
Study NCT02004626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kollagenase
Description: Conduction of security tests: complete coagulation and glycosylated hemoglobin. Volunteers in childbearing age, with β-HCG (human chorionic gonadotropin) test.~Verification of anthropometric data, clinical evaluation, PU evaluation, randomization and treatment start.~Wash the wound with 0.9 % sterile saline solution; Apply of the investigational product directly in the devitalized tissue (necrotic tissue and Slough).~Cover the wound with sterile gauze and dry transparent film. The procedures for the exchange of bandages must be done every day, twice a day until the total debridement of devitalized tissue.~Photographic records.
Study NCT01061528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Nicotine
Description: Participants will use the full strength 21mg. patch for 4 weeks, will taper to the 14 mg. patch for the next 2 weeks, and then to the 7 mg. patch for the remaining 2 weeks of treatment.
Study NCT01061528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal Nicotine
Description: Participants will use the full strength 21mg. patch for 4 weeks, will taper to the 14 mg. patch for the next 2 weeks, and then to the 7 mg. patch for the remaining 2 weeks of treatment.
Study NCT01006161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 527123
Description: Low dose
Study NCT01006161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 527123
Description: Medium dose
Study NCT01006161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 527123
Description: High dose
Study NCT01006161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SCH 527123
Description: Placebo to match SCH 527123
Study NCT04627129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR2554 and Itraconazole
Description: Single dose of oral administration of SHR2554 and Multiple dose of oral of Itraconazole Capsules
Study NCT00661778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab was supplied as a sterile liquid in glass vials.
Study NCT00661778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Bevacizumab was supplied as a sterile liquid in glass vials.
Study NCT01425814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAS100977
Description: Dry powder inhalation,Once daily, single dose
Study NCT01425814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference
Description: Dry powder inhalation (capsule),single dose
Study NCT01425814 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dry powder inhalation or Dry powder inhalation (capsule),Once daily, single dose
Study NCT00002529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: cyclophosphamide 600 mg/m2 i.v. day 1) every 21 days
Study NCT00661778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Bevacizumab was supplied as a sterile liquid in glass vials.
Study NCT03174054 — intervention group
Intervention type: PROCEDURE
Intervention: Biopsy
Description: Biopsies are part of standard procedures in the patients recruited and will not be done due to this study.
Study NCT01306864 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemospray Kit
Description: Hemostasis of Arterial GI Bleeding
Study NCT03823534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: IV Ketorolac to be given over the course of the first 24 hours after surgery. See arm/group description for further details.
Study NCT03823534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: An IV normal saline placebo prepared by the hospital pharmacy.
Study NCT03823534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: acetaminophen 500 mg PO Q4 hours PRN for mild pain
Study NCT03823534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: acetaminophen 500 mg PO Q4 hours PRN for mild pain
Study NCT03823534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone Acetaminophen
Description: oxycodone-acetaminophen 5-325 mg PO Q4 hours PRN for moderate to severe pain
Study NCT03823534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone Acetaminophen
Description: oxycodone-acetaminophen 5-325 mg PO Q4 hours PRN for moderate to severe pain
Study NCT03823534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: morphine IV PRN (or other opioid) for severe breakthrough pain
Study NCT03823534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: morphine IV PRN (or other opioid) for severe breakthrough pain
Study NCT03823534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrocodone/Acetaminophen
Description: At discharge, patients will be prescribed 1-2 hydrocodone-acetaminophen 5-325 mg Q4 hours. Those with preexisting liver disease will be prescribed the equivalent in oxycodone.
Study NCT03823534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocodone/Acetaminophen
Description: At discharge, patients will be prescribed 1-2 hydrocodone-acetaminophen 5-325 mg Q4 hours. Those with preexisting liver disease will be prescribed the equivalent in oxycodone.
Study NCT03823534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycodone
Description: Upon discharge, patients will be prescribed the equivalent of 1-2 hydrocodone 5mg Q4 hours upon should they have preexisting liver disease and are unable to consume acetaminophen.
Study NCT03823534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Upon discharge, patients will be prescribed the equivalent of 1-2 hydrocodone 5mg Q4 hours upon should they have preexisting liver disease and are unable to consume acetaminophen.
Study NCT02421081 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vessel microsurgery
Description: That is a surgery ro repair artery laceration.
Study NCT02421081 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tendon repair
Description: That is a surgery ro repair tendon cut.
Study NCT02421081 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nerve microsurgery
Description: That is a surgery ro repair median/ ulnar/ radial nerve cut.
Study NCT04456543 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pressure monitoring
Description: garment pressures were monitored using the portable pressure measuring device and the compression garment was adjusted so that the pressure was maintained at the therapeutic range of 15 - 25 mmHg.
Study NCT04456543 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pressure monitoring
Description: garment pressures were monitored using the portable pressure measuring device and the compression garment was adjusted so that the pressure was maintained at the therapeutic range of 15 - 25 mmHg.
Study NCT03702530 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 2x 50 L3 larvae infection
Description: After (mock) immunisation, infection with 50 Necator americanus larvae at week 13 and 15
Study NCT01604057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZT-034 Low Dose Nasal Spray
Description: Nasal Spray
Study NCT01604057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZT-034 Mid Dose Nasal Spray
Description: Nasal Spray
Study NCT01604057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZT-034 High Dose Nasal Spray
Description: Nasal Spray
Study NCT01604057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: 20 mcg subcutaneous daily
Study NCT01604057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nasal Spray
Study NCT00555048 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Study NCT00555048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Study NCT00555048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00555048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT00555048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Study NCT05112146 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein isolate
Description: Oral administration
Study NCT05112146 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein microgel
Description: Oral administration
Study NCT05112146 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Oral administration
Study NCT04438668 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Centaflow and Standard Care
Description: The intervention is screening methods
Study NCT04438668 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: The intervention is screening methods
Study NCT03061552 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: sonographic measurement of inferior vena cava diameter
Description: pre-dialysis measurement of inferior vena cava diameter using echocardiography
Study NCT02590042 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADSC-SVF-002
Description: ADSC-SVF with the following identity:~Less than or equal to 10% each CD34 and CD45 positive cells At least 70% each CD90, CD73 and CD105 positive cells Viability of at least 85% Mean Florescence Intensity of less than or equal to 100 C12FDG 0-5-2.5x10\^6 cells/g of liposuctioned (hydrated fat)
Study NCT00750022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Individuals will receive standard dietary plan. Women will receive 1200 Kcal/day and men will receive 1600 Kcal/day. Individuals will receive RMR measurement at three months. RMR information will be used to help improve eating behavior.
Study NCT00335335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iodixanol
Study NCT00604201 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood
Description: unrelated umbilical cord blood will be co-infused with haploidentical CD34-selected cells from a related donor for treatment of severe aplastic anemia and myelodysplastic syndrome.
Study NCT00164749 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and ginkgo extract
Description: Placebo once daily, either as capsules or as powder to be mixed with food. All patients also received 120 mg/day standardized ginkgo leaf extract.
Study NCT00164749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin and ginkgo extract
Description: 1 g curcumin once daily, either as capsules or as powder to be mixed with food. All patients also received 120 mg/day standardized ginkgo leaf extract.
Study NCT00002529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: doxorubicin 60 mg/m2 i.v. day 1) every 21 days, intravenous.
Study NCT00164749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin and ginkgo extract
Description: 4 g curcumin once daily, either as capsules or as powder to be mixed with food. All patients also received 120 mg/day standardized ginkgo leaf extract.
Study NCT00720226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan 100 mg daily
Study NCT00720226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill daily
Study NCT00671073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oglemilast
Description: Oglemilast low dose, oral administration, once daily for 12 weeks
Study NCT00671073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, oral administration, once daily for 12 weeks
Study NCT00671073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oglemilast
Description: Oglemilast middle dose, oral administration, once daily for 12 weeks
Study NCT00671073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oglemilast
Description: Oglemilast high dose, oral administration, once daily for 12 weeks
Study NCT03504761 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClariCore Optical Biopsy System
Description: Demonstrate the efficacy and safety of the ClariCore System in obtaining prostate biopsies utilizing real-time tissue classification.
Study NCT04658316 — intervention group
Intervention type: BEHAVIORAL
Intervention: Iowa Oral Performance Instrument
Description: Use Iowa Oral Performance Instrument to measure tongue pressure and swallowing tongue pressure
Study NCT02116517 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: green tea extract
Description: 500 mg three times per day
Study NCT02116517 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: green tea extract
Description: 500 mg three times per day
Study NCT02116517 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: cellulose 500mg three times a day for 6 weeks
Study NCT02116517 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: cellulose 500mg three times a day for 6 weeks
Study NCT04403217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized structured dietary plan based on MD
Description: Participants will follow an individualized structured dietary plan based on Mediterranean diet for 12 weeks
Study NCT04587908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-205 [Ambulatory Cohort] [Non-ambulatory Cohort]
Description: ・Treatment period：oral administration for 52 weeks, BID after meal
Study NCT04587908 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo [Ambulatory Cohort] only
Description: * Observation period：oral administration for 2 weeks, BID after meal~* Treatment period：oral administration for 52 weeks, BID after meal
Study NCT02133001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine 84 mg will be self-administered by participants as intranasal spray as two times a week, for 4 weeks (that is, Day 1,4,8,11,15,18,22,25). Dose may be reduced to 56 mg per day based on Investigator's discretion.
Study NCT02133001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be self-administered by participants as intranasal spray as two times a week, for 4 weeks (that is, Day 1,4,8,11,15,18,22,25).
Study NCT03778723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA)
Description: Propofol (1.5-2 mg/kg/h) infusion, Midazolam (0.12 mg/kg/h) infusion
Study NCT03778723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhalation Anesthesia
Description: Sevoflurane at a concentration of 2-2.5%
Study NCT00002529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride
Description: epirubicin 90 mg/m2 i.v. day 1) every 21 days, intravenous.
Study NCT00002529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Tamoxifen 20 mg daily.
Study NCT00002529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: toremifene
Description: Toremifene 60 mg daily.
Study NCT01385579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care manager outreach
Description: Patients assigned to the intervention arm are mailed a letter informing them that they are due for colorectal cancer screening, educational information about colorectal cancer screening, a fecal occult blood testing (FOBT) kit, and directions on how to complete and return the FOBT kit. Patients who do not respond to the mail outreach received up to 3 attempts at telephone outreach by the care manager.
Study NCT01681147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2 online nutrition and exercise education classes
Description: Two online nutrition and physical activity classes will accessed from a computer, android phone or a tablet. Each class is estimated to last about 1.5- 2 hours and will be accessed 6 weeks-3 months and 9 months
Study NCT03427255 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT group treatment-plus
Description: The CBT group program-plus consists of 3 1- hr CBT couple sessions and 10 2-hr CBT group sessions over a period of 6 months. The manualized treatment comprise, pain- and sexual education, relaxation and gradual exposure exercises as well as sensate focus and sexual communication exercises for the couple. 6-8 women participate in each group. Two psychologists conduct the couple and group sessions.
Study NCT03427255 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CBT group treatment-plus
Description: The CBT group program-plus consists of 3 1- hr CBT couple sessions and 10 2-hr CBT group sessions over a period of 6 months. The manualized treatment comprise, pain- and sexual education, relaxation and gradual exposure exercises as well as sensate focus and sexual communication exercises for the couple. 6-8 women participate in each group. Two psychologists conduct the couple and group sessions.
Study NCT03427255 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waiting-list control condition
Description: Waiting-list control condition during length of active treatment (6 months).
Study NCT04368858 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Exploratory physiopathology study, including non-invasive functional explorations carried out in patients with chronic pathology.
Description: In the Mobility Exploration Unit of the University Hospital of Clermont-Ferrand, patients with chronic illnesses undergo a complete assessment of their physical capacities as well as their nutritional status. For the purpose of this protocol, patients will have to perform 2 functional tests, namely the TM6 and the TUG, while being equipped with inertial sensor units (mTUG® and mGAIT®). The data of the gait analysis, posturography and strength analyses as well as the questionnaires' scores will be taken into account in this research. At 6 months and at 1 year, occurrence of a fall will be recorded in order to prospectively monitor this parameter.
Study NCT01681147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self monitoring of blood glucose levels
Description: Self monitoring of blood glucose levels four times a day for four consecutive days once a month from 6 weeks-3 months through 9 months post partum
Study NCT02971176 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose protocol computed tomography
Description: Radiation dose under the low-dose protocol computed tomography (120 kilovolt, 15 milliampere seconds)
Study NCT02971176 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard-dose protocol computed tomography
Description: Radiation dose under the standard-dose protocol computed tomography (120 kilovolt, 150 milliampere seconds)
Study NCT02845063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: concentric cardiovascular training
Description: Subjects will carry out 8 weeks of cardiovascular training by an interval type of protocol that includes a high repetition number of concentric type contractions on a softrobotic device.
Study NCT02845063 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: concentric cardiovascular training
Description: Subjects will carry out 8 weeks of cardiovascular training by an interval type of protocol that includes a high repetition number of concentric type contractions on a softrobotic device.
Study NCT02845063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eccentric cardiovascular training
Description: Subjects will carry out 8 weeks of cardiovascular training by an interval type of protocol that includes a high repetition number of eccentric type contractions on a softrobotic device.
Study NCT02845063 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eccentric cardiovascular training
Description: Subjects will carry out 8 weeks of cardiovascular training by an interval type of protocol that includes a high repetition number of eccentric type contractions on a softrobotic device.